Phase 1 Study of M9466 Combined With Carboplatin and Platinum-based Anticancer Therapy (DDRiver 521)
- Conditions
- Interventions
- First Posted Date
- 2024-12-06
- Last Posted Date
- 2024-12-06
- Target Recruit Count
- 54
- Registration Number
- NCT06719973
- Locations
- ๐บ๐ธ
Please Contact U.S. Medical Information, Billerica, Massachusetts, United States
๐ฉ๐ชPlease Contact the Communication Center, Darmstadt, Germany
Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)
- Conditions
- Interventions
- First Posted Date
- 2024-11-28
- Last Posted Date
- 2024-11-28
- Target Recruit Count
- 250
- Registration Number
- NCT06710132
- Locations
- ๐ฉ๐ช
Research Site, Darmstadt, Germany
Anti-GD2 ADC M3554 in Advanced Solid Tumors
- First Posted Date
- 2024-10-15
- Last Posted Date
- 2024-12-06
- Target Recruit Count
- 52
- Registration Number
- NCT06641908
- Locations
- ๐บ๐ธ
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
๐บ๐ธMemorial Sloan-Kettering Cancer Center (MSKCC) - New York - Memorial Sloan Kettering Cancer Center (CC)- Westc, New York, New York, United States
๐บ๐ธThe University of Texas MD Anderson Cancer Center, Houston, Texas, United States
M9466 in Combination With Topoisomerase 1 Inhibitors-based Regimens in Advanced Solid Tumors and Colorectal Cancer (DDRiver 511)
- Conditions
- Interventions
- First Posted Date
- 2024-07-19
- Last Posted Date
- 2024-12-10
- Target Recruit Count
- 54
- Registration Number
- NCT06509906
- Locations
- ๐บ๐ธ
Sarah Cannon Research Institute at Health One, Denver, Colorado, United States
๐ฆ๐บSt George Private Hospital, Kogarah, Australia
๐ฆ๐บPeter MacCallum Cancer Centre - Use the one with Account 2 VCCC, Parkville, Australia
Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302)
- Conditions
- Interventions
- First Posted Date
- 2024-05-29
- Last Posted Date
- 2024-11-26
- Target Recruit Count
- 60
- Registration Number
- NCT06433219
- Locations
- ๐ช๐ธ
Hospital Universitario Ramon y Cajal - Servicio de Oncologia, Madrid, Spain
๐ช๐ธHospital Universitario 12 de Octubre - Servicio de Oncologia, Madrid, Spain
๐จ๐ญKantonsspital Frauenfeld - 150509250, Frauenfeld, Switzerland
Study of Avelumab and Tuvusertib in Participants With Advanced Urothelial Cancer That Has Progressed on Prior Anti-PD-(L)1 Therapy (JAVELIN DDRiver Bladder)
- First Posted Date
- 2024-05-22
- Last Posted Date
- 2024-07-31
- Target Recruit Count
- 70
- Registration Number
- NCT06424717
- Locations
- ๐ฉ๐ช
Please Contact the Communication Center, Darmstadt, Germany
๐บ๐ธPlease Contact U.S. Medical Information, Rockland, Massachusetts, United States
M9466 Alone or in Combination in Advanced Solid Tumors (DDriver 501)
- Conditions
- Interventions
- First Posted Date
- 2024-05-20
- Last Posted Date
- 2024-12-19
- Target Recruit Count
- 96
- Registration Number
- NCT06421935
- Locations
- ๐ฐ๐ท
Asan Medical Center, Seoul, Korea, Republic of
๐ฐ๐ทSeverance Hospital, Yonsei University Health System - Division of Infectious Diseases, Seoul, Korea, Republic of
๐ช๐ธHospital Universitari Vall d'Hebron - Oncology Dept., Barcelona, Spain
Phase 1b Safety Study of Xevinapant, Weekly Cisplatin, and RT in Participants With Unresected LA SCCHN (HyperlynX)
- Conditions
- Interventions
- First Posted Date
- 2023-09-28
- Last Posted Date
- 2024-07-18
- Target Recruit Count
- 18
- Registration Number
- NCT06056310
- Locations
- ๐บ๐ธ
Mount Sinai Comprehensive Cancer Center, Miami Beach, Florida, United States
๐บ๐ธMontefiore Medical Center PRIME, Bronx, New York, United States
๐ง๐ชUniversitair Ziekenhuis Gent - Medical Oncology, Gent, Belgium
Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322)
- First Posted Date
- 2023-05-31
- Last Posted Date
- 2024-08-15
- Target Recruit Count
- 180
- Registration Number
- NCT05882734
- Locations
- ๐ง๐ช
CHU de Liรจge - PARENT, Liege, Belgium
๐บ๐ธUPMC Cancer Center, Pittsburgh, Pennsylvania, United States
๐บ๐ธUCLA Hematology and Oncology - Santa Monica, Santa Monica, California, United States
Study of M5049 in DM and PM Participants (NEPTUNIA)
- Conditions
- Interventions
- First Posted Date
- 2022-12-14
- Last Posted Date
- 2024-11-27
- Target Recruit Count
- 40
- Registration Number
- NCT05650567
- Locations
- ๐บ๐ธ
Augusta University-Rheumatology, Augusta, Georgia, United States
๐บ๐ธUniversity of Pittsburgh, Pittsburgh, Pennsylvania, United States
๐บ๐ธJohns Hopkins University - Department of Medicine, Division of Rheumatology, Baltimore, Maryland, United States